EP3681508A4 - Verfahren und zusammensetzung zur behandlung von virusinfektionen - Google Patents

Verfahren und zusammensetzung zur behandlung von virusinfektionen Download PDF

Info

Publication number
EP3681508A4
EP3681508A4 EP18857189.7A EP18857189A EP3681508A4 EP 3681508 A4 EP3681508 A4 EP 3681508A4 EP 18857189 A EP18857189 A EP 18857189A EP 3681508 A4 EP3681508 A4 EP 3681508A4
Authority
EP
European Patent Office
Prior art keywords
composition
viral infection
treating viral
treating
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18857189.7A
Other languages
English (en)
French (fr)
Other versions
EP3681508A1 (de
Inventor
Robert A. Newman
Otis C. Addington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phoenix Biotechnology Inc
Original Assignee
Phoenix Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/051553 external-priority patent/WO2018053123A1/en
Application filed by Phoenix Biotechnology Inc filed Critical Phoenix Biotechnology Inc
Publication of EP3681508A1 publication Critical patent/EP3681508A1/de
Publication of EP3681508A4 publication Critical patent/EP3681508A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EP18857189.7A 2017-09-14 2018-07-16 Verfahren und zusammensetzung zur behandlung von virusinfektionen Pending EP3681508A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2017/051553 WO2018053123A1 (en) 2016-09-14 2017-09-14 Method and compositions for treating viral infection
US201862698365P 2018-07-16 2018-07-16
PCT/US2018/042226 WO2019055119A1 (en) 2017-09-14 2018-07-16 METHOD AND COMPOSITION FOR TREATING VIRAL INFECTION

Publications (2)

Publication Number Publication Date
EP3681508A1 EP3681508A1 (de) 2020-07-22
EP3681508A4 true EP3681508A4 (de) 2021-05-19

Family

ID=65723839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18857189.7A Pending EP3681508A4 (de) 2017-09-14 2018-07-16 Verfahren und zusammensetzung zur behandlung von virusinfektionen

Country Status (9)

Country Link
EP (1) EP3681508A4 (de)
JP (3) JP6820450B2 (de)
KR (2) KR20210107904A (de)
AU (2) AU2018334386B2 (de)
CA (1) CA3075729A1 (de)
IL (2) IL285232B (de)
MX (1) MX2020002883A (de)
RU (1) RU2020113341A (de)
WO (1) WO2019055119A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4009981B1 (de) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Verfahren und zusammensetzungen zur behandlung von coronavirusinfektionen
CN114209711A (zh) * 2020-03-31 2022-03-22 菲尼克斯生物技术公司 用于治疗冠状病毒感染的方法和组合物
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
SG11202105728YA (en) * 2020-03-31 2021-11-29 Phoenix Biotechnology Inc Method and compositions for treating coronavirus infection
FR3109297A1 (fr) * 2020-04-19 2021-10-22 Ephyla « Nouvel inhibiteur non protéique de furine »
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT84857B (pt) 1986-05-13 1990-02-08 Huseyin Ziya Ozel Processo para a preparacao de extractos de plantas da especie nerium e de composicoes farmaceuticas que os contem
US5236132A (en) 1992-01-03 1993-08-17 Vortec, Inc. Gradient-force comminuter/dehydrator apparatus and method
US5598979A (en) 1995-04-20 1997-02-04 Vortec, Inc. Closed loop gradient force comminuting and dehydrating system
CA2191923C (en) 1996-12-03 2000-10-24 Ji-Won Yoon Portulaca oleracea and tumor cell growth
AU761879B2 (en) 1998-05-19 2003-06-12 Research Development Foundation Triterpene compositions and methods for use thereof
JP2002526452A (ja) 1998-09-24 2002-08-20 オゼル・ファーマスーティカルズ・インコーポレイテッド キョウチクトウ抽出物、その医薬組成物及びその調整方法
US6517015B2 (en) 2000-03-21 2003-02-11 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
AU8494601A (en) 2000-08-18 2002-03-04 Univ Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV
US9931316B2 (en) * 2004-01-06 2018-04-03 Paul Edward Stamets Antiviral activity from medicinal mushrooms and their active constituents
US6715705B2 (en) 2001-03-16 2004-04-06 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
ATE295087T1 (de) 2001-04-09 2005-05-15 Loders Croklaan Bv Konzentrat von triterpenen
EP1476031A1 (de) 2001-05-11 2004-11-17 University of Ottawa Angstlösende zusammensetzungen der marcgraviaceae enthaltend betulinsäure, deren derivate und verfahren
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
JP2005527611A (ja) * 2002-05-28 2005-09-15 ヘンリー エム．ジャクソン ファウンデーション フォー ジ アドバンスメント オブ ミリタリー メディシン、インク． 嚢胞性線維症およびその他のｉｌ−８依存性疾患治療用の強心配糖体
AU2003287526A1 (en) 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
US20050026849A1 (en) 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
EP1730163A4 (de) 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmazeutische salze von 3-o-(3,3-dimethylsuccinyl)betulinsäure
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
US8022055B2 (en) 2005-02-09 2011-09-20 Dabur Pharma Limited Betulinic acid derivatives
CA2603124A1 (en) 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Selective oxidation of triterpenes employing tempo
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
US20090131714A1 (en) 2005-06-08 2009-05-21 Krasutsky Pavel A Synthesis of betulonic and betulinic aldehydes
WO2006132033A1 (ja) 2005-06-10 2006-12-14 Pola Chemical Industries Inc. 新規トリテルペン酸誘導体及びそれを含有してなる皮膚外用剤
US7402325B2 (en) * 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
AU2006333084A1 (en) 2005-12-16 2007-07-12 Panacos Pharmaceuticals, Inc. Preparation of pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
EP1803461A1 (de) * 2005-12-27 2007-07-04 Heinz-Herbert Fiebig Therapeutische Verwendung eines Nerium-oleander Blätterextrakts
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
US20090203661A1 (en) 2006-10-12 2009-08-13 Safe Stephen H Betulinic acid, derivatives and analogs thereof and uses therefor
TW200837074A (en) 2006-11-03 2008-09-16 Panacos Pharmaceuticals Inc Extended triterpene derivatives
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
RU2571687C2 (ru) 2007-11-13 2015-12-20 Феникс Байотекнолоджи Инк. Набор для определения вероятности терапевтического ответа на противораковую химиотерапию сердечным гликозидом
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
LT2271658T (lt) 2008-04-18 2017-02-27 Reata Pharmaceuticals, Inc. Antioksidantai uždegimo moduliatoriai:oleanolio rūgšties c-17 patvirtinti dariniai
US7915402B2 (en) 2008-04-18 2011-03-29 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
CN102083442B (zh) 2008-04-18 2014-08-13 里亚塔医药公司 抗氧化剂炎症调节剂：在c-17具有氨基和其它修饰的齐墩果酸衍生物
WO2010028487A1 (en) 2008-09-10 2010-03-18 Université Du Québec À Chicoutimi Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
CN101704872B (zh) 2009-11-23 2012-06-27 张南 23-羟基白桦酸衍生物、其制备方法及应用
US8685469B2 (en) 2009-11-30 2014-04-01 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
KR101774181B1 (ko) 2010-01-11 2017-09-01 피닉스 바이오테크놀러지 인코포레이티드. 강심 배당체로 신경계 질환을 치료하는 방법
TWI386415B (zh) 2010-02-02 2013-02-21 Univ Kaohsiung Medical 熊果酸衍生物及其醫藥組合物
TWI410431B (zh) 2010-12-22 2013-10-01 Ind Tech Res Inst 齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途
US20140221328A1 (en) 2011-01-10 2014-08-07 Bandi Parthasaradhi Reddy Pharmaceutically acceptable salts of novel betulinic acid derivatives
EP2670764B1 (de) 2011-01-31 2015-09-02 Bristol-Myers Squibb Company C-28-amine aus modifizierten c-3-betulinsäurederivaten als hiv-reifungshemmer
CN102558280B (zh) 2011-11-18 2014-09-17 温州大学 一种30-卤代桦木酸的生产方法
WO2013079018A1 (zh) 2011-12-01 2013-06-06 杭州本生药业有限公司 2-位取代的齐墩果酸衍生物、及其制备方法和应用
WO2013079024A1 (zh) 2011-12-01 2013-06-06 杭州本生药业有限公司 齐墩果酸酰胺化衍生物、及其制备方法和应用
WO2013160810A2 (en) 2012-04-24 2013-10-31 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
KR101889528B1 (ko) 2012-08-14 2018-08-17 넥스올리고(주) 신규한 우르솔릭산 유도체 및 이의 제조 방법
HUE044126T2 (hu) 2012-09-10 2019-09-30 Reata Pharmaceuticals Inc Oleanolsav C17-alkándiil- és alkéndiil-származékai, és eljárás azok elõállítására
LT2892911T (lt) 2012-09-10 2017-11-10 Reata Pharmaceuticals, Inc. Oleanolinės rūgšties c17 heteroarilo dariniai ir jų panaudojimo būdas
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
EA027861B1 (ru) 2013-02-25 2017-09-29 Бристол-Майерс Сквибб Компани C-3 алкил- и алкенилмодифицированные производные бетулиновой кислоты или их фармацевтические соли, противовирусная фармацевтическая композиция и фармацевтическая композиция для лечения вич на их основе
WO2015121168A1 (de) * 2014-02-12 2015-08-20 Organobalance Gmbh Hefe-stamm und mikrobielles verfahren zur produktion von pentazyklischen triterpenen und/oder triterpenoiden
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US9492438B2 (en) * 2014-07-25 2016-11-15 Bette Pollard Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system
CA2987132A1 (en) * 2015-06-08 2016-12-15 Dermarc, Llc Therapeutic composition

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ASHBROOK ALISON W. ET AL: "Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection", MBIO, 24 May 2016 (2016-05-24), pages 1 - 14, XP055792193, Retrieved from the Internet <URL:https://mbio.asm.org/content/mbio/7/3/e00693-16.full.pdf> [retrieved on 20210401], DOI: 10.1128/mBio.00693-16 *
AVCI OGUZHAN ET AL: "Nerium Oleander Distilati'nin Blue Tongue Virus Üzerine in vitro Etkisi In vitro Effect of Nerium Oleander Distillate on Blue Tongue Virus", AVKAE DERG, vol. 4, 1 January 2014 (2014-01-01), pages 14 - 18, XP055792186 *
DWIVEDI VIVEK DHAR ET AL: "In silico evaluation of inhibitory potential of triterpenoids from Azadirachta indica against therapeutic target of dengue virus, NS2B-NS3 protease.", JOURNAL OF VECTOR BORNE DISEASES, vol. 53, no. 2, April 2016 (2016-04-01), pages 156 - 161, XP002802578, ISSN: 0972-9062 *
FU XU ET AL: "Novel Chemical Ligands to Ebola Virus and Marburg Virus Nucleoproteins Identified by Combining Affinity Mass Spectrometry and Metabolomics Approaches", SCIENTIFIC REPORTS, vol. 6, no. 1, 12 July 2016 (2016-07-12), XP055792762, Retrieved from the Internet <URL:http://www.nature.com/articles/srep29680.pdf> DOI: 10.1038/srep29680 *
GUPTA VIKAS ET AL: "PHYTOCHEMICAL AND PHARMACOLOGICAL POTENTIAL OF NERIUM OLEANDER: A REVIEW", INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, vol. 1, no. 3, 1 January 2010 (2010-01-01), pages 21 - 27, XP055792176 *
OGUZHAN AVCI ET AL: "Determination of in Vitro Antiviral Activity of Nerium Oleander Distillate against to Parainfluenza-3 Virus", ANIMAL AND VETERINARY SCIENCES, vol. 2, no. 5, 1 January 2014 (2014-01-01), pages 150 - 153, XP055762391, ISSN: 2328-5842, DOI: 10.11648/j.avs.20140205.14 *
RAJBHANDARI M. ET AL: "Screening of Nepalese medicinal plants for antiviral activity", JOURNAL OF ETHNOPHARMACOLOGY, vol. 74, 1 January 2001 (2001-01-01), pages 251 - 255, XP055792595 *
SINGH SHAILBALA ET AL: "Nerium oleanderderived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity", FITOTERAPIA, IDB HOLDING, MILAN, IT, vol. 84, 2 November 2012 (2012-11-02), pages 32 - 39, XP028968939, ISSN: 0367-326X, DOI: 10.1016/J.FITOTE.2012.10.017 *
VAN KANEGAN MICHAEL J. ET AL: "Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke", SCIENTIFIC REPORTS, vol. 6, no. 1, 1 May 2016 (2016-05-01), XP055791907, Retrieved from the Internet <URL:http://www.nature.com/articles/srep25626> DOI: 10.1038/srep25626 *

Also Published As

Publication number Publication date
JP6820450B2 (ja) 2021-01-27
JP7037673B2 (ja) 2022-03-16
JP2020534293A (ja) 2020-11-26
IL285232B (en) 2022-07-01
AU2020204236A1 (en) 2020-07-16
KR20210107904A (ko) 2021-09-01
KR20200081356A (ko) 2020-07-07
IL285232A (en) 2021-09-30
MX2020002883A (es) 2020-10-05
AU2018334386A1 (en) 2020-04-02
JP2021063105A (ja) 2021-04-22
RU2020113341A3 (de) 2021-10-15
JP2022075755A (ja) 2022-05-18
CA3075729A1 (en) 2019-03-21
AU2018334386B2 (en) 2021-11-04
IL273162B (en) 2021-08-31
EP3681508A1 (de) 2020-07-22
AU2020204236B2 (en) 2020-12-10
IL273162A (en) 2020-04-30
WO2019055119A1 (en) 2019-03-21
KR102295179B1 (ko) 2021-08-30
RU2020113341A (ru) 2021-10-15

Similar Documents

Publication Publication Date Title
EP3139954A4 (de) Verfahren und zusammensetzungen zur behandlung von hepatitis-b-vireninfektionen
EP3512524A4 (de) Verfahren und zusammensetzungen zur behandlung von virusinfektionen
EP3684377A4 (de) Verfahren zur behandlung von hepatitis-b-infektionen
EP3653630A4 (de) Endocyclische thiamidinoamid-arylamid-verbindung und verwendung davon zur behandlung von hepatitis b
EP3681508A4 (de) Verfahren und zusammensetzung zur behandlung von virusinfektionen
EP3374350A4 (de) Hydroxypyridinon- und hydroxypyrimidinon-basierte verbindungen zur behandlung von bakteriellen infektionen
EP3442502A4 (de) Zusammensetzungen, systeme, kits und verfahren zur behandlung von infektionen
EP3432891A4 (de) Verfahren zur behandlung und prävention von c. difficile
EP3468593A4 (de) Zusammensetzungen und verfahren zur vorbeugung und behandlung einer zika-virus-infektion
EP3268010A4 (de) Zusammensetzungen und verfahren zur behandlung von bakterieninfektionen
EP3634431A4 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von hepatitis b
EP3280422A4 (de) Zusammensetzungen und verfahren zur behandlung einer hbv-infektion
EP3728307A4 (de) Zusammensetzungen und verfahren zur behandlung von hiv/aids mit immuntherapie
EP3317290A4 (de) Zusammensetzungen und verfahren zur behandlung einer virusinfektion
EP3250553A4 (de) Zusammensetzungen und verfahren zur hemmung viraler infektionen
EP3166637A4 (de) Zusammensetzungen und verfahren zur behandlung einer dengue-virusinfektion
EP3310382A4 (de) Zusammensetzungen und verfahren zur modulation viraler infektionen
EP3675813A4 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung viraler infektionen
EP3352729A4 (de) Verfahren und zusammensetzungen zur hautbehandlung
ZA202202370B (en) Compositions and methods for treating viral infections
EP3833387A4 (de) Zusammensetzungen und verfahren zur vorbeugung und behandlung einer virusinfektion
EP3411367A4 (de) Zusammensetzungen und verfahren zur behandlung von infektionen
EP3400008A4 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von hepatitis b
EP3534913A4 (de) Zusammensetzung und verfahren zur behandlung von otitis
EP3538108A4 (de) Verfahren zur behandlung oder inhibition einer ebola-virus-infektion

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031560000

Ipc: A61K0036240000

A4 Supplementary search report drawn up and despatched

Effective date: 20210416

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 36/24 20060101AFI20210409BHEP

Ipc: A61K 31/56 20060101ALI20210409BHEP

Ipc: A61K 31/7042 20060101ALI20210409BHEP

Ipc: A61K 31/7048 20060101ALI20210409BHEP

Ipc: A61P 31/12 20060101ALI20210409BHEP

Ipc: A61P 31/14 20060101ALI20210409BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221004

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230921

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN